Lv2
160 积分 2025-02-22 加入
Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study
1天前
已完结
Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa
1天前
已完结
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
1天前
已完结
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study
1天前
已完结
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies*
1天前
已完结
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study
1天前
已完结
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
1天前
已完结
Open‐label pilot study of tofacitinib 2% for the treatment of refractory vitiligo
24天前
已完结
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study
24天前
已完结
Oral JAK Inhibitors in Adolescent Vitiligo: A Real-World Retrospective Study on Treatment Response and Recurrence
24天前
已完结
皖公网安备34019202002308
